ascopubs.org

GATA6 expression with CA19-9 levels as biomarkers in resectable pancreatic adenocarcinoma treated with neoadjuvant modified FOLFIRINOX in the NeoPancONE trial.

Inflammatory and immune marker dynamics following intratumoral alpha dart for pancreatic cancer. A: CA19-9 <200 U/mL, GATA6 high (n=31) 40.9 27.1 B: CA19-9 <200 U/mL, GATA6 low (n=7) 36.9 21.8 C: CA19 ...
ascopubs.org

Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma

High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell–Supported Transplantation: Long-Term Survival Update Four hundred twenty-four consecutive patients with pancreatic ...
Medscape

In Pancreatic Cancer, If CA 19-9 Is Up, Then Chemo First

Changing the standard sequence of treatment for operable pancreatic cancer could improve survival for some patients, say researchers. Some patients with operable disease and elevated levels of the CA ...
EurekAlert!

Investigational blood biomarker panel may improve detection of pancreatic cancer

Bottom Line: A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal ...
EurekAlert!

Integrating anatomy and biology for a better pancreatic cancer prognosis

Recent advancements in pancreatic cancer prognosis have led to the development of the Tianjin Grading System, a tool integrating both anatomical resectability and tumor biological parameters. This ...